koko体育app

欢迎来到《koko体育app 学报（医学版）》
李向龙, 朱焕玲, 刘红英等. 酪氨酸激酶抑制剂治疗慢性粒细胞白血病的临床疗效分析[J]. koko体育app 学报（医学版）, 2014, 45(4): 647-651.
引用本文: 李向龙, 朱焕玲, 刘红英等. 酪氨酸激酶调节剂制疗萎缩性粒神经元koko体育app 白血病的临床实践辽效概述[J]. 广东学校学报（医学检验版）, 2014, 45(4): 647-651.
LI Xiang-long, ZHU Huan-ling, LIU Hong-ying. et al. Efficacy of Tyrosine Kinase Inhibitor in Treatment of Chronic Myeloid Leukemia Patients[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 647-651.
Citation: LI Xiang-long, ZHU Huan-ling, LIU Hong-ying. et al. Efficacy of Tyrosine Kinase Inhibitor in Treatment of Chronic Myeloid Leukemia Patients[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 647-651.

酪氨酸激酶抑制剂治疗慢性粒细胞白血病的临床疗效分析

Efficacy of Tyrosine Kinase Inhibitor in Treatment of Chronic Myeloid Leukemia Patients

  • 摘要: 目的 回顾性分析酪氨酸激酶抑制剂(TKI)治疗慢性粒细胞白血病(CML)的临床疗效。方法 对近十年来在我院门诊接受治疗的655例CML患者的临床资料及随访结果进行回顾性分析。其中551例患者为慢性期，62例为加速期，42例为急变期。83例患者仅接受了干扰素治疗，572例接受了伊马替尼（慢性期400 mg/d，加速/急变期600 mg/d）。治疗期间定期监测患者血液学、细胞及分子遗传学反应，参照2011年版CML指南评价治疗反应及疗效，采用Kaplan-Meier曲线进行生存分析。结果 随访结束时总完全血液学缓解（CHR）、主要细胞遗传学缓解（MCyR）、完全细胞遗传学缓解（CCyR）和主要分子生物学缓解（MMR）率分别为92.1%、75.8%、73.1%和47.9%。所有患者总体1年、3年、5年和10年总生存（OS）率为(96.3±0.8)%、(86.3±1.8)%、(79.0±2.4)% 和(66.5±4.8)%，1年、3年、5年和10年无事件生存（EFS）率为(92.2±1.1)%、(77.9±2.1)%、(67.9±6.8)% 和(35.8±6.0)%，慢性期患者累积获得CHR、MCyR、CCyR和MMR的比例分别达到98.7%、82.5%、79.4%和52.4%。加速期和急变期患者，其疗效显著降低。早慢性期疗效好于晚慢性期，尽早开始TKI治疗能使患者明显获益，早期分子学反应预示更好的远期疗效，伊马替尼耐药的患者换用二代TKI后，随访结束时MCyR率为43.5%，MMR率为25.5%。 结论 慢性期CML患者接受TKI治疗的疗效及预后较好，且越早用药，疗效和预后也越好。  
    Abstract: Objective To evaluate the effects of tyrosine kinase inhibitors （TKI） in the treatment of chronic myeloid leukemia. Methods There were total 655 cases of chronic myeloid leukemia treated in one single-institution enrolled in this study. The dosage of TKI Imatinib was 400 mg/d for chronic phase, 600 mg/d for accelerated and blast phase respectively. Complete blood count, cytogenetic and molecular studies were regularly monitored during the course of therapy. The therapeutic effect was evaluated and the survival analysis was performed. Results The total complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and major molecular response (MMR) rates were 92.1%, 75.8% ，73.1% and 47.9% respectively.1-year, 3-year, 5-year and 10-year overall survival (OS) rates were(96.3±0.8)%, (86.3±1.8)%, (79.0±2.4)% and (66.5±4.8)% respectively. 1 year, 3-year, 5-year and 10-year event-free survival (EFS) rates were(92.2±1.1)%, (77.9±2.1)%, (67.9±6.8)% and (35.8±6.0)% respectively.The proportion of the patients in chronic phase achieving CHR, MCyR, CCyR and MMR were 98.7%, 82.5%, 79.4% and 52.4% respectivly. Compared with chronic phase patients, the efficacy of IM in the treatment of accelerated phase and blast phase patients was significantly lower. The effect of TKI in early chronic phase was better than that in late chronic phase. Early molecular response was associated with a better 5-year EFS, but not OS. Conclusion CML patients in chronic phase treated with TKI have a better outcome. The earlier TKI be used, the better the prognosis and efficacy be achieved.  
    • HTML全文
© 2014 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取🌠 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!